Compare TOON & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOON | TVRD |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 27.5M |
| IPO Year | 2014 | 2013 |
| Metric | TOON | TVRD |
|---|---|---|
| Price | $0.51 | $0.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.11 |
| AVG Volume (30 Days) | ★ 230.9K | 138.4K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.26 | ★ 79.01 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $39,353,000.00 | $911,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.74 | ★ N/A |
| Revenue Growth | 20.75 | ★ 959.30 |
| 52 Week Low | $0.50 | $0.83 |
| 52 Week High | $1.29 | $5.69 |
| Indicator | TOON | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 27.14 |
| Support Level | $0.50 | N/A |
| Resistance Level | $0.63 | $1.09 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 16.27 | 5.71 |
Kartoon Studios Inc is a media company developing, producing, marketing, and licensing branded animated entertainment properties and consumer products for media and retail distribution. Its portfolio features programming for toddlers to tweens, including the preschool properties Rainbow Rangers for Nick Jr. and Llama Llama for Netflix, Stan Lee's Superhero Kindergarten, Shaq's Garage, toddler brand Baby Genius, STEM-based series Thomas Edison's Secret Lab, Warren Buffett's Secret Millionaires Club, and the new preschool show, Stan Lee's Superhero Kindergarten. Its channel is available on television and mobile devices through distribution platforms, including Comcast, Cox, DISH, Sling TV, Apple TV, Roku, Android TV, Tubi, Xumo, and Amazon Fire.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.